NEW YORK – BioHemp International, Inc. (OTC: BKIT), (“Company”) announced a research opinion on the company is now available for download.
Report Highlights
– To establish multi-tier distribution channels for CBD products
– To acquire strong CBD assets through consolidation
– CEO background in private equity and business development
– Pending portfolio of diversified CBD assets
The Company strategy is to roll up multi-branded e-commerce and brick & mortar retailers under one platform, while focusing on acquiring strong CBD assets through consolidation across the CBD industry. By creating these economies of scale for brands and vendors, the Company is positioning itself to be a major CBD distribution channel within the industry.
For this reason, Ludlow Research initiated research coverage on BKIT with a short-term ‘speculative’ target of $2.50 to $3.50 based on their rollup strategy to build multi-leveled distribution platform targeting existing CBD consumer, wholesalers, and retailers.
To download the full report, risks, and disclosures on this company please visit: https://ludlowresearch.com/reports.
About BioHemp International, Inc.
BioHemp International (OTC: BKIT) is a Company focused on rolling up a distribution platform for CBD providers to become the leading consolidation force in the CBD industry. For more information, view the Company’s website BioHempInternational.com
